

Media Release

Contact:

Dr. Franco Merckling,
CEO, Kenta Biotech
Tel. +41 58 680 52 75
info@kentabiotech.com

Change of Leadership at Kenta Biotech AG

Dr Franco Merckling has been appointed CEO of Kenta Biotech AG („Kenta“), effective September 15th, 2011.

He will ensure both the continuity of our R&D activities and the strategic evolution of the company.

Dr Merckling who holds a PhD in chemistry, has a solid and successful track record in Sales & Marketing as well as General Management both in Switzerland and abroad with “Big Pharma” companies.

Franco Merckling follows Violetta Georgescu-Kyburz, who has successfully lead the company since its foundation in 2006. Together with the Kenta research and development teams she has been able to build a large portfolio of monoclonal antibodies for the treatment of life-threatening hospital infections.

About Kenta Biotech

Kenta Biotech is pioneering the research and development of fully human antibodies that are desperately needed for the treatment of severe hospital-acquired infections. Antibodies generated from Kenta's proprietary MAbIgX® technology effectively target bacteria independently of resistance to antimicrobial agents. Furthermore, the MAbIgX® technology enables the company to test therapeutically promising antibodies against a variety of targets within a short period of time. Kenta's pipeline includes a series of genuinely human antibodies to target pathogens causing life-threatening hospital infections, such as *P. aeruginosa*, *S. aureus* and *A. baumannii*.

Kenta Biotech was founded in 2006 and is headquartered in Berne, Switzerland. The company is financed by independent private investors and management who together hold the company share capital. For more information, visit www.kentabiotech.com